Dipexium Pharmaceuti (DPRX) 12.57 $DPRX Dipexium

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 1:25 PM

Dipexium Pharmaceuti (DPRX) 12.57 $DPRX

Dipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5%
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:45AM CDT
Dipexium Pharmaceuticals, Inc. (DPRX) was a big mover last session, as the company saw its shares rise over 8% on the day.
BSTC: 37.35 (+0.76), DPRX: 12.57 (-0.13)

Dipexium Pharmaceuticals Announces Participation in September Investor Conferences
PR Newswire - Wed Aug 24, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced plans to participate in two September investor conferences:
DPRX: 12.57 (-0.13)

Dipexium Pharmaceuticals Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2016.
DPRX: 12.57 (-0.13)

Dipexium Pharmaceuticals to Hold Second Quarter 2016 Financial Results Conference Call on Thursday, August 4, 2016, at 8:30 a.m. ET
PR Newswire - Thu Jul 28, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended June 30, 2016, on Thursday, August 4, 2016 at 7:00 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments and answer questions.
DPRX: 12.57 (-0.13)

Dipexium Pharmaceuticals' Locilex® Microbiology Data Presented at ASM Microbe 2016 Conference
PR Newswire - Mon Jun 20, 3:01PM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), and research collaborator, R. M. Alden Research Laboratory, announced that data from two new Locilex® microbiology studies were presented at the American Society for Microbiology's Microbe conference in Boston, Massachusetts, June 16-20, 2016.
DPRX: 12.57 (-0.13)

Dipexium Announces Completion of Enrollment Objective in OneStep-1 Pivotal Phase 3 Clinical Trial
PR Newswire Europe - Mon May 16, 7:01AM CDT
Both Pivotal Phase 3 Clinical Trials Are Now Completed
DPRX: 12.57 (-0.13)

Dipexium Pharmaceuticals Announces Completion of Enrollment Objective in OneStep-2 Pivotal Phase 3 Clinical Trial and First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced that it has completed the patient enrollment objective in the OneStep-2 pivotal Phase 3 clinical trial in accordance with the requirements set forth in the OneStep-2 clinical trial protocol. The Company also announced that the OneStep-1 pivotal Phase 3 clinical trial has passed the 98% enrollment mark and is expected to reach the 180 patient enrollment objective imminently. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration (FDA) and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers (Mild DFI).
DPRX: 12.57 (-0.13)

Dipexium Pharmaceuticals to Hold First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016, at 8:30 a.m. ET
PR Newswire - Mon May 09, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) will release its financial results for the quarter ended March 31, 2016, on Thursday, May 12, 2016 at 7:00 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments and answer questions.
DPRX: 12.57 (-0.13)

Dipexium Pharmaceuticals (DPRX) Jumps: Stock Rises 7.5%
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 7:40AM CDT
Dipexium Pharmaceuticals, Inc. (DPRX) saw its shares rise above 7% in the last trading session.
DPRX: 12.57 (-0.13)

Will Dipexium Pharmaceuticals (DPRX) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 7:03AM CDT
As of late, it has definitely been a great time to be an investor in Dipexium Pharmaceuticals Inc (DPRX)
DPRX: 12.57 (-0.13)

Why You Shouldn't Bet Against Dipexium Pharmaceuticals (DPRX) Stock
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:52AM CDT
Dipexium Pharmaceuticals (DPRX) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry
DPRX: 12.57 (-0.13)

Dipexium Pharmaceuticals Announces Issuance of Locilex® Patent in Japan
PR Newswire - Mon Mar 28, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antimicrobial peptide, today announced that the government of Japan has issued a Locilex patent. The patent claims are directed to a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033.
DPRX: 12.57 (-0.13)

Dipexium Pharmaceuticals Reports 2015 Financial Results
PR Newswire - Wed Mar 23, 6:00AM CDT
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antimicrobial peptide, today announced operational and financial results for the year ended December 31, 2015.
DPRX: 12.57 (-0.13)

Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 2:50PM CST
Dipexium (DPRX) attains 75% enrollment milestone in two phase III studies on Locilex for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 12.57 (-0.13), OSIR: 5.09 (+0.08), LGND: 106.88 (+3.57), ANIK: 47.45 (+0.21)

Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials
PR Newswire - Thu Feb 04, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced its OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone, in the aggregate, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials (180 patients per clinical trial) being conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 12.57 (-0.13)

Dipexium Pharmaceuticals Announces Issuance of Locilex® Patents in Australia and New Zealand
PR Newswire - Mon Feb 01, 7:00AM CST
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced that the governments of Australia and New Zealand have issued new Locilex patents. The patents' claims are directed to a novel formulation of Locilex, an antibiotic peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections. Both issued patents have expiry dates in June 2033.
DPRX: 12.57 (-0.13)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Geron Corp Faces Fiduciary Duty Investigation

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

AI and Storytelling Make Waves in Science Education

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...